Myocardial perfusion imaging using a technetium-99m Sestamibi in asymptomatic and low risk for coronary artery disease patients with diagnosed systemic lupus erythematosus

Perfusion

Volumn 26, Issue 2, 2011, Pages 151-157

  Baharfard, Nastaran ^a   Mohammad Kazem Shiroodi, ^a   Fotoohi, Freidoon ^a   Samangooie, Shahdokht ^a   Isa Neshandar Asli, ^a   Eghtesadi Araghi, Payam ^b   Javadi, Hamid ^c   Semnani, Shahryar ^c   Amini, Azam ^d   Assadi, Majid ^d  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Parsteb Pajouheshyar Medical Sciences Research Institute (NGO)   (Iran)

^c GOLESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d BUSHEHR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

coronary artery disease; myocardial perfusion imaging.; risk factors; SPECT; systemic lupus erythematosus

Indexed keywords

C REACTIVE PROTEIN; CARDIOLIPIN ANTIBODY; COMPLEMENT; CORTICOSTEROID; DIPYRIDAMOLE; DOUBLE STRANDED DNA ANTIBODY; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD CELL COUNT; BODY MASS; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; CORONARY RISK; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DISEASE DURATION; DISEASE SEVERITY; DYSLIPIDEMIA; FAMILY HISTORY; FEMALE; HEART MUSCLE PERFUSION; HUMAN; HYPERTENSION; MENOPAUSE; MYOCARDIAL DISEASE; MYOCARDIAL PERFUSION IMAGING; PHARMACOLOGIC STRESS TESTING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; CORONARY ARTERY DISEASE; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; RISK FACTORS; TECHNETIUM TC 99M SESTAMIBI; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; YOUNG ADULT;

EID: 79953099390     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1177/0267659110389844     Document Type: Article

References (47)

1. Asanuma Y., Oeser A., Shintani AK, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003 Dec 18; 349 (25). 2407-2415. (Pubitemid 37542989)
2. Roman MJ, Shanker BA, Davis A., et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003 Dec 18; 349 (25). 2399-2406. (Pubitemid 37542988)
3. Sella EM, Sato EI, Leite WA, Oliveira Filho JA, Barbieri A. Myocardial perfusion scintigraphy and coronary disease risk factors in systemic lupus erythematosus. Ann Rheum Dis 2003 Nov; 62 (11). 1066-1070. (Pubitemid 37323570)
4. Sella EM, Sato EI, Barbieri A. Coronary artery angiography in systemic lupus erythematosus patients with abnormal myocardial perfusion scintigraphy. Arthritis Rheum 2003 Nov; 48 (11). 3168-3175. (Pubitemid 37409328)
5. Bessant R., Duncan R., Ambler G., et al. Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: a case-control study. Arthritis Rheum 2006 Dec 15; 55 (6). 892-899. (Pubitemid 44917462)
6. Sun SS, Shiau YC, Tsai SC, Lin CC, Kao A., Lee CC The role of technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography (SPECT) in the detection of cardiovascular involvement in systemic lupus erythematosus patients with non-specific chest complaints. Rheumatology (Oxford) 2001 Oct; 40 (10). 1106-1111.
7. Goldberg RJ, Urowitz MB, Ibanez D., Nikpour M., Gladman DD Risk factors for development of coronary artery disease in women with systemic lupus erythematosus. J Rheumatol 2009 Nov; 36 (11). 2454-2461.
8. Schillaci O., Lagana B., Danieli R., et al. Technetium-99m sestamibi single-photon emission tomography detects subclinical myocardial perfusion abnormalities in patients with systemic lupus erythematosus. Eur J Nucl Med 1999 Jul; 26 (7). 713-717. (Pubitemid 29338659)
9. Bruce IN, Burns RJ, Gladman DD, Urowitz MB Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. I. Prevalence and distribution of abnormalities. J Rheumatol 2000 Oct; 27 (10). 2372-2377.
10. Lin CC, Ding HJ, Chen YW, Wang JJ, Ho ST, Kao A. Usefulness of technetium-99m sestamibi myocardial perfusion SPECT in detection of cardiovascular involvement in patients with systemic lupus erythematosus or systemic sclerosis. Int J Cardiol 2003 Dec; 92 (2-3). 157-161. (Pubitemid 37509976)
11. 1996 National Heart Foundation clinical guidelines for the assessment and management of dyslipidaemia. Dyslipidaemia Advisory Group on behalf of the scientific committee of the National Heart Foundation of New Zealand. N Z Med J 1996 Jun 28; 109 (1024). 224-231.
12. Czuszynska Z., Romanowicz G. Myocardial perfusion in women with systemic lupus erythomatosus and no symptoms of coronary artery disease. Nucl Med Rev Cent East Eur 2004 ; 7 (2). 171-174.
13. Hosenpud JD, Montanaro A., Hart MV, et al. Myocardial perfusion abnormalities in asymptomatic patients with systemic lupus erythematosus. Am J Med 1984 Au g; 77 (2). 286-292. (Pubitemid 14098638)
14. McLaughlin MG, Danias PG Transient ischemic dilation: a powerful diagnostic and prognostic finding of stress myocardial perfusion imaging. J Nucl Cardiol 2002 Nov-Dec; 9 (6). 663-667. (Pubitemid 36050213)
15. Nikpour M., Gladman DD, Ibanez D., Bruce IN, Burns RJ, Urowitz MB Myocardial perfusion imaging in assessing risk of coronary events in patients with systemic lupus erythematosus. J Rheumatol 2009 Feb; 36 (2). 288-294.
16. Beller GA Pharmacologic stress imaging. JAMA 1991 Feb 6; 265 (5). 633-638.
17. Iskandrian AS Adenosine myocardial perfusion imaging. J Nucl Med 1994 Apr; 35 (4). 734-736. (Pubitemid 24114580)
18. Slart RH, Tio RA, Zijlstra F., Dierckx RA Diagnostic pathway of integrated SPECT/CT for coronary artery disease. Eur J Nucl Med Mol Imaging 2009 Nov; 36 (11). 1829-1834.
19. Underwood SR, Anagnostopoulos C., Cerqueira M., et al. Myocardial perfusion scintigraphy: the evidence. Eur J Nucl Med Mol Imaging 2004 Feb; 31 (2). 261-291.
20. Kaminek M., Myslivecek M., Husak V., et al. The accuracy of myocardial perfusion SPECT imaging in the evaluation of coronary artery disease in women and men. Nucl Med Rev Cent East Eur 2001 ; 4 (2). 69-72.
21. Fard-Esfahani A., Assadi M., Saghari M., et al. The role of myocardial perfusion imaging in the evaluation of patients undergoing percutaneous transluminal coronary angioplasty. Hellenic J Cardiol 2009 Sep-Oct; 50 (5). 396-401.
22. Cooper JA, McCandless BK Preventing patient motion during tomographic myocardial perfusion imaging. J Nucl Med 1995 Nov; 36 (11). 2001-2005.
23. Pitman AG, Kalff V., Van Every B., Risa B., Barnden LR, Kelly MJ Contributions of subdiaphragmatic activity, attenuation, and diaphragmatic motion to inferior wall artifact in attenuation-corrected Tc-99m myocardial perfusion SPECT. J Nucl Cardiol 2005 Jul-Aug; 12 (4). 401-409. (Pubitemid 41093757)
24. Heller GV, Bateman TM, Johnson LL, et al. Clinical value of attenuation correction in stress-only Tc-99m sestamibi SPECT imaging. J Nucl Cardiol 2004 May-Jun; 11 (3). 273-281. (Pubitemid 38950252)
25. Bengel FM, Schwaiger M. Nuclear medicine studies of the heart. Eur Radiol 1998 ; 8 (9). 1698-1706. (Pubitemid 128662723)
26. Lagana B., Schillaci O., Tubani L., et al. Lupus carditis: evaluation with technetium-99m MIBI myocardial SPECT and heart rate variability. Angiology 1999 Feb; 50 (2). 143-148. (Pubitemid 29086804)
27. Alqaisi F., Albadarin F., Jaffery Z., et al. Prognostic predictors and outcomes in patients with abnormal myocardial perfusion imaging and angiographically insignificant coronary artery disease. J Nucl Cardiol 2008 Nov-Dec; 15 (6). 754-761.
28. Delcour KS, Khaja A., Chockalingam A., Kuppuswamy S., Dresser T. Outcomes in patients with abnormal myocardial perfusion imaging and normal coronary angiogram. Angiology 2009 Jun-Jul; 60 (3). 318-321.
29. Rasulova N., Singh A., Demetriadou O., et al. Clinical significance of myocardial perfusion abnormalities in patients with varying degree of coronary artery stenosis. Nucl Med Commun 2008 Feb; 29 (2). 129-136. (Pubitemid 350306770)
30. Gimelli A., Marzullo P., L'Abbate A., Rovai D. 'False-positive' myocardial perfusion imaging: correlation with cardiovascular risk factors and effect on event-free survival. J Cardiovasc Med (Hagerstown) 2008 Jul; 9 (7). 707-713.
31. Adamu U., Knollmann D., Almutairi B., et al. Stress/rest myocardial perfusion scintigraphy in patients without significant coronary artery disease. J Nucl Cardiol 2010 Jan-Feb; 17 (1). 38-44.
32. Soman P., Dave DM, Udelson JE, et al. Vascular endothelial dysfunction is associated with reversible myocardial perfusion defects in the absence of obstructive coronary artery disease. J Nucl Cardiol 2006 Nov; 13 (6). 756-760. (Pubitemid 44890810)
33. Iskandrian AE The Achilles heel of SPECT imaging: the false-positive scans - or are they? J Nucl Cardiol Nov 2006 Nov; 13 (6). 747-748. (Pubitemid 44890813)
34. Storto G., Sorrentino AR, Pellegrino T., Liuzzi R., Petretta M., Cuocolo A. Assessment of coronary flow reserve by sestamibi imaging in patients with typical chest pain and normal coronary arteries. Eur J Nucl Med Mol Imaging 2007 Au g; 34 (8). 1156-1161. (Pubitemid 47290657)
35. Ammann P., Naegeli B., Rickli H., et al. Characteristics of patients with abnormal stress technetium Tc 99m sestamibi SPECT studies without significant coronary artery diameter stenoses. Clin Cardiol 2003 Nov; 26 (11). 521-524. (Pubitemid 37346089)
36. Nishioka T., Amanullah AM, Luo H., et al. Clinical validation of intravascular ultrasound imaging for assessment of coronary stenosis severity: comparison with stress myocardial perfusion imaging. J Am Coll Cardiol 1999 Jun; 33 (7). 1870-1878.
37. Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 2008 Mar 11; 117 (10). 1283-1291. (Pubitemid 351365675)
38. Doria A., Shoenfeld Y., Wu R., et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003 Nov; 62 (11). 1071-1077. (Pubitemid 37323571)
39. Maksimowicz-McKinnon K., Magder LS, Petri M. Predictors of carotid atherosclerosis in systemic lupus erythematosus. J Rheumatol 2006 Dec; 33 (12). 2458-2463. (Pubitemid 46067826)
40. Haque S., Gordon C., Isenberg D., et al. Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study. J Rheumatol 2010 Feb; 37 (2). 322-329.
41. Petri M., Perez-Gutthann S., Spence D., Hochberg MC Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992 Nov; 93 (5). 513-519.
42. Manzi S., Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997 Mar 1; 145 (5). 408-415. (Pubitemid 27084212)
43. Jonsson H., Nived O., Sturfelt G. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine (Baltimore) 1989 May; 68 (3). 141-150. (Pubitemid 19132411)
44. Gladman DD, Urowitz MB Morbidity in systemic lupus erythematosus. J Rheumatol Suppl 1987 Jun; 14 Suppl 13: 223-226.
45. Asherson RA, Khamashta MA, Baguley E., Oakley CM, Rowell NR, Hughes GR Myocardial infarction and antiphospholipid antibodies in SLE and related disorders. Q J Med 1989 Dec; 73 (272). 1103-1115. (Pubitemid 20019604)
46. de Bandt M., Benali K., Guillevin L., et al. Longitudinal determination of antiphospholipid antibodies in lupus patients without previous manifestations of antiphospholipid syndrome. A prospective study. J Rheumatol 1999 Jan; 26 (1). 91-96. (Pubitemid 29051402)
47. Ghirardello A., Doria A., Ruffatti A., et al. Antiphospholipid antibodies (aPL) in systemic lupus erythematosus. Are they specific tools for the diagnosis of aPL syndrome? Ann Rheum Dis 1994 Feb; 53 (2). 140-142. (Pubitemid 24087369)